These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 31581176)

  • 1. Activation of GLP-1 receptors attenuates oxycodone taking and seeking without compromising the antinociceptive effects of oxycodone in rats.
    Zhang Y; Kahng MW; Elkind JA; Weir VR; Hernandez NS; Stein LM; Schmidt HD
    Neuropsychopharmacology; 2020 Feb; 45(3):451-461. PubMed ID: 31581176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel dual agonist of glucagon-like peptide-1 receptors and neuropeptide Y2 receptors attenuates fentanyl taking and seeking in male rats.
    Zhang Y; Rahematpura S; Ragnini KH; Moreno A; Stecyk KS; Kahng MW; Milliken BT; Hayes MR; Doyle RP; Schmidt HD
    Neuropharmacology; 2021 Jul; 192():108599. PubMed ID: 33965397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucagon-like peptide-1 receptor activation in the ventral tegmental area attenuates cocaine seeking in rats.
    Hernandez NS; Ige KY; Mietlicki-Baase EG; Molina-Castro GC; Turner CA; Hayes MR; Schmidt HD
    Neuropsychopharmacology; 2018 Sep; 43(10):2000-2008. PubMed ID: 29497166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats.
    Hernandez NS; O'Donovan B; Ortinski PI; Schmidt HD
    Addict Biol; 2019 Mar; 24(2):170-181. PubMed ID: 29226617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADX106772, an mGlu2 receptor positive allosteric modulator, selectively attenuates oxycodone taking and seeking.
    Illenberger JM; Flores-Ramirez FJ; Matzeu A; Lütjens R; Martin-Fardon R
    Neuropharmacology; 2023 Nov; 238():109666. PubMed ID: 37463637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The novel dopamine D3 receptor antagonists/partial agonists CAB2-015 and BAK4-54 inhibit oxycodone-taking and oxycodone-seeking behavior in rats.
    You ZB; Gao JT; Bi GH; He Y; Boateng C; Cao J; Gardner EL; Newman AH; Xi ZX
    Neuropharmacology; 2017 Nov; 126():190-199. PubMed ID: 28888944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon-Like Peptide-1 Receptor Activation in the Ventral Tegmental Area Decreases the Reinforcing Efficacy of Cocaine.
    Schmidt HD; Mietlicki-Baase EG; Ige KY; Maurer JJ; Reiner DJ; Zimmer DJ; Van Nest DS; Guercio LA; Wimmer ME; Olivos DR; De Jonghe BC; Hayes MR
    Neuropsychopharmacology; 2016 Jun; 41(7):1917-28. PubMed ID: 26675243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PYY
    Caffrey A; Lavecchia E; Merkel R; Zhang Y; Chichura KS; Hayes MR; Doyle RP; Schmidt HD
    Neuropharmacology; 2023 Nov; 239():109686. PubMed ID: 37572954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine D
    You ZB; Bi GH; Galaj E; Kumar V; Cao J; Gadiano A; Rais R; Slusher BS; Gardner EL; Xi ZX; Newman AH
    Neuropsychopharmacology; 2019 Jul; 44(8):1415-1424. PubMed ID: 30555159
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral Effects of Opioid Full and Partial Agonists During Chronic Buprenorphine Treatment.
    Withey SL; Spealman RD; Bergman J; Paronis CA
    J Pharmacol Exp Ther; 2019 Nov; 371(2):544-554. PubMed ID: 31413139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerance and cross-tolerance to the antinociceptive effects of oxycodone and the imidazoline I
    Thorn DA; Zhang Y; Li JX
    Psychopharmacology (Berl); 2017 Jun; 234(12):1871-1880. PubMed ID: 28314949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antinociception by spinal and systemic oxycodone: why does the route make a difference? In vitro and in vivo studies in rats.
    Lemberg KK; Kontinen VK; Siiskonen AO; Viljakka KM; Yli-Kauhaluoma JT; Korpi ER; Kalso EA
    Anesthesiology; 2006 Oct; 105(4):801-12. PubMed ID: 17006080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide-1 receptor agonist, exendin-4, reduces reinstatement of heroin-seeking behavior in rats.
    Douton JE; Augusto C; Stoltzfus B; Carkaci-Salli N; Vrana KE; Grigson PS
    Behav Pharmacol; 2021 Jun; 32(4):265-277. PubMed ID: 33229892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the orexin system for prescription opioid use disorder: Orexin-1 receptor blockade prevents oxycodone taking and seeking in rats.
    Matzeu A; Martin-Fardon R
    Neuropharmacology; 2020 Mar; 164():107906. PubMed ID: 31841797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GLP-1 receptor signaling in the laterodorsal tegmental nucleus attenuates cocaine seeking by activating GABAergic circuits that project to the VTA.
    Hernandez NS; Weir VR; Ragnini K; Merkel R; Zhang Y; Mace K; Rich MT; Christopher Pierce R; Schmidt HD
    Mol Psychiatry; 2021 Aug; 26(8):4394-4408. PubMed ID: 33257815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats.
    Fulenwider HD; Nennig SE; Hafeez H; Price ME; Baruffaldi F; Pravetoni M; Cheng K; Rice KC; Manvich DF; Schank JR
    Addict Biol; 2020 Nov; 25(6):e12822. PubMed ID: 31830773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cooperative activation of D1-like and D2-like dopamine receptors in the nucleus accumbens shell is required for the reinstatement of cocaine-seeking behavior in the rat.
    Schmidt HD; Pierce RC
    Neuroscience; 2006 Oct; 142(2):451-61. PubMed ID: 16844308
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central GLP-1 receptors: Novel molecular targets for cocaine use disorder.
    Hernandez NS; Schmidt HD
    Physiol Behav; 2019 Jul; 206():93-105. PubMed ID: 30930091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of tradipitant, a selective NK1 antagonist, on response to oxycodone in humans.
    Coe MA; Lofwall MR; Vessels V; Nuzzo PA; Walsh SL
    Psychopharmacology (Berl); 2021 Jul; 238(7):1857-1866. PubMed ID: 33988725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of sub-antinociceptive doses of oxycodone and morphine produces marked antinociceptive synergy with reduced CNS side-effects in rats.
    Ross FB; Wallis SC; Smith MT
    Pain; 2000 Feb; 84(2-3):421-8. PubMed ID: 10666549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.